NewLink Genetics, which is developing a Phase 3 drug for surgically-resected pancreatic cancer patients, raised $43 million by offering 6.2 million shares (vs. planned 5.5 million) at $7, below the range of $10 to $12. At the offer price, NewLink commands a...read more
With the Groupon IPO successfully floated and the FTSE Renaissance US IPO Index running ahead of the S&P 500 (+14.5% vs +11.5%, respectively) this quarter, the IPO floodgates have opened as...read more
Coming off of a strong previous week, worldwide IPO performance took a step backward this week as global markets continued to feel the wrath of the European Debt Crisis. While Greek bailout talks carry on, investors remain cautious to commit to global equities. ...read more
NewLink Genetics prices IPO at $7, below the range
NewLink Genetics, which is developing a Phase 3 drug for surgically-resected pancreatic cancer patients, raised $43 million by offering 6.2 million shares (vs. planned 5.5 million) at $7, below the range of $10 to $12. At the offer price, NewLink commands a...read more
US IPO Calendar erupts, 16 deals set to price in November
With the Groupon IPO successfully floated and the FTSE Renaissance US IPO Index running ahead of the S&P 500 (+14.5% vs +11.5%, respectively) this quarter, the IPO floodgates have opened as...read more
5 IPOs planned for the week of Nov 7
The following IPOs are expected to price this week:
Chesapeake Granite Wash Trust (CHKR), which owns royalty interests in established and horizontal development wells in...read more
Weekly Recap: Groupon arrives as global IPO market takes small step back
Coming off of a strong previous week, worldwide IPO performance took a step backward this week as global markets continued to feel the wrath of the European Debt Crisis. While Greek bailout talks carry on, investors remain cautious to commit to global equities. ...read more